FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2140307375> ?p ?o ?g. }

• W2140307375 endingPage "124" @default.
• W2140307375 startingPage "67" @default.
• W2140307375 abstract "Incretin-based therapies, including the use of incretin mimetics of glucagon-like peptide-1 receptor (GLP-1R) agonists and incretin enhancers of dipeptidyl-peptidase 4 (DPP-4) inhibitors, are widely used by clinicians for glucose lowering in patients with type 2 diabetes mellitus. These agents have benefits of a lower risk of hypoglycemia, being neutral for body weight for DPP-4 inhibitors and having a potential for weight reduction with GLP-1R agonists. They may also have a neutral or beneficial cardiovascular effect. Despite these benefits, an increased risk of cancer (especially pancreatic cancer and thyroid cancer) associated with incretin-based therapies has been reported. In this article, we reviewed related literature of experimental animal and observational human studies, clinical trials, and meta-analyses published until December 15, 2014. Current studies suggested a probable role of GLP-1R activation on the development of pancreatic cancer and thyroid cancer in rodents, but such an effect in humans is not remarkable due to the lower or lack of expression of GLP-1R on human pancreatic ductal cells and thyroid tissues. Findings in human studies are controversial and inconclusive. In the analyses of the US Food and Drug Administration adverse events reporting system, a significantly higher risk of pancreatic cancer was observed for GLP-1R agonists and DPP-4 inhibitors, but a significantly higher risk of thyroid cancer was only observed for GLP-1R agonists. Such a higher risk of pancreatic cancer or thyroid cancer could not be similarly demonstrated in other human observational studies or analyses of data from clinical trials. With regards to cancers other than pancreatic cancer and thyroid cancer, available studies supported a neutral association in humans. Some preliminary studies even suggested a potentially beneficial effect on the development of other cancers with the use of incretins. Based on current evidence, continuous monitoring of the cancer issues related to incretin-based therapies is required, even though the benefits may outweigh the potential cancer risk in the general patients with type 2 diabetes mellitus." @default.
• W2140307375 created "2016-06-24" @default.
• W2140307375 creator A5038889667 @default.
• W2140307375 creator A5061349374 @default.
• W2140307375 creator A5075440697 @default.
• W2140307375 date "2015-01-02" @default.
• W2140307375 modified "2023-10-13" @default.
• W2140307375 title "An Updated Review on Cancer Risk Associated with Incretin Mimetics and Enhancers" @default.
• W2140307375 cites W113695330 @default.
• W2140307375 cites W1503093115 @default.
• W2140307375 cites W1547073044 @default.
• W2140307375 cites W1551563477 @default.
• W2140307375 cites W1579228515 @default.
• W2140307375 cites W1713993122 @default.
• W2140307375 cites W1909761377 @default.
• W2140307375 cites W1963703214 @default.
• W2140307375 cites W1964132180 @default.
• W2140307375 cites W1964886571 @default.
• W2140307375 cites W1965893446 @default.
• W2140307375 cites W1967516239 @default.
• W2140307375 cites W1968089068 @default.
• W2140307375 cites W1968568631 @default.
• W2140307375 cites W1968758146 @default.
• W2140307375 cites W1970592992 @default.
• W2140307375 cites W1974415625 @default.
• W2140307375 cites W1976838333 @default.
• W2140307375 cites W1977218630 @default.
• W2140307375 cites W1979288606 @default.
• W2140307375 cites W1979684707 @default.
• W2140307375 cites W1986937516 @default.
• W2140307375 cites W1988236655 @default.
• W2140307375 cites W1988804967 @default.
• W2140307375 cites W1989937660 @default.
• W2140307375 cites W1990896956 @default.
• W2140307375 cites W1991913334 @default.
• W2140307375 cites W1992617702 @default.
• W2140307375 cites W1993624198 @default.
• W2140307375 cites W1995090069 @default.
• W2140307375 cites W1995566056 @default.
• W2140307375 cites W1995734875 @default.
• W2140307375 cites W1998249838 @default.
• W2140307375 cites W1998401806 @default.
• W2140307375 cites W1998679419 @default.
• W2140307375 cites W2000074754 @default.
• W2140307375 cites W2001477956 @default.
• W2140307375 cites W2004409542 @default.
• W2140307375 cites W2004507412 @default.
• W2140307375 cites W2005146299 @default.
• W2140307375 cites W2006826279 @default.
• W2140307375 cites W2008114298 @default.
• W2140307375 cites W2009294215 @default.
• W2140307375 cites W2009969219 @default.
• W2140307375 cites W2011899971 @default.
• W2140307375 cites W2013308281 @default.
• W2140307375 cites W2014783132 @default.
• W2140307375 cites W2018786845 @default.
• W2140307375 cites W2020637822 @default.
• W2140307375 cites W2020816546 @default.
• W2140307375 cites W2021692067 @default.
• W2140307375 cites W2021979767 @default.
• W2140307375 cites W2022096337 @default.
• W2140307375 cites W2025634024 @default.
• W2140307375 cites W2027081774 @default.
• W2140307375 cites W2027317575 @default.
• W2140307375 cites W2030855481 @default.
• W2140307375 cites W2031078511 @default.
• W2140307375 cites W2031848004 @default.
• W2140307375 cites W2034667874 @default.
• W2140307375 cites W2035957915 @default.
• W2140307375 cites W2036554445 @default.
• W2140307375 cites W2037465277 @default.
• W2140307375 cites W2042425867 @default.
• W2140307375 cites W2043614750 @default.
• W2140307375 cites W2044486670 @default.
• W2140307375 cites W2049717993 @default.
• W2140307375 cites W2050938327 @default.
• W2140307375 cites W2051631407 @default.
• W2140307375 cites W2054498677 @default.
• W2140307375 cites W2054925541 @default.
• W2140307375 cites W2058514432 @default.
• W2140307375 cites W2058922633 @default.
• W2140307375 cites W2061738696 @default.
• W2140307375 cites W2062096499 @default.
• W2140307375 cites W2063865446 @default.
• W2140307375 cites W2064072028 @default.
• W2140307375 cites W2064130493 @default.
• W2140307375 cites W2065417819 @default.
• W2140307375 cites W2066987382 @default.
• W2140307375 cites W2067663978 @default.
• W2140307375 cites W2068341308 @default.
• W2140307375 cites W2069497231 @default.
• W2140307375 cites W2072451938 @default.
• W2140307375 cites W2075070224 @default.
• W2140307375 cites W2075514437 @default.
• W2140307375 cites W2075764167 @default.
• W2140307375 cites W2079440907 @default.
• W2140307375 cites W2079839541 @default.
• W2140307375 cites W2080703854 @default.

• next